# CARDIAC RSK3 INHIBITORS, LLC: CRI-103 gene therapy as Investigational New Drug for Dilated Cardiomyopathy

**Lab Budget Score:** 70/100

| Field | Value |
|---|---|
| Organization | CARDIAC RSK3 INHIBITORS, LLC |
| Location | LOS ALTOS, CA |
| Project | CRI-103 gene therapy as Investigational New Drug for Dilated Cardiomyopathy |
| Project number | 2R44HL167349-03 |
| Mechanism | R44 |
| Institute | National Heart Lung and Blood Institute |
| Award | $1,159,408 |
| Awarded | 2026-09-17 |
| Project period | 2023-09-14 to 2029-08-31 |
| UEI | D38ER7T7B8L8 |

## Why this score
- Award of $1M or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11292808). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.